Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2016 by Stemline Therapeutics, Inc.
Information provided by (Responsible Party):
Stemline Therapeutics, Inc. Identifier:
First received: November 3, 2015
Last updated: January 31, 2017
Last verified: February 2016
Study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in patients with Advanced Solid Tumors

Condition Intervention Phase
Solid Tumors
Drug: SL-801
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors

Further study details as provided by Stemline Therapeutics, Inc.:

Primary Outcome Measures:
  • Safety [ Time Frame: Up to 2 years ]
    The percentage of patients experiencing treatment-related and treatment-emergent adverse events

Secondary Outcome Measures:
  • Determine the half-life of SL-801in plasma [ Time Frame: Up to 2 Years ]
  • Progression Free Survival [ Time Frame: Up to 2 years ]
  • Overall Response Rate [ Time Frame: Up to 2 years ]
  • Overall Survival [ Time Frame: Up to 2 Years ]
  • Determine the maximum concentration of SL-801 in plasma [ Time Frame: Up to 2 years ]

Estimated Enrollment: 50
Study Start Date: February 2016
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SL-801
The study medication, SL-801 consists of tablets to be administered orally. The initial planned schedule involves administration daily on Days 1 through Day 4 and Days 8 through Day 11 of each cycle of therapy. A cycle of therapy is 21 days. The scheduled starting dose is 5 mg.
Drug: SL-801

Detailed Description:

Study SL-801-0115 is a first-in-human, dose-escalation study in patients with advanced (i.e., metastatic or locally advanced and unresectable) solid tumors that are resistant to or relapsed following available standard systemic therapy or for which there is no standard systemic therapy and additional radiation therapy or other loco-regional therapies are not considered feasible. Eligible patients will be enrolled and receive treatment with SL-801 in a 21-day cycle. SL-801 will be administered orally and the dose regimen will depend on the cohort in which the patient is enrolled.

The study plans to enroll 40-50 adult patients at multiple study centers in the US.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patient must have histologic or cytologic evidence of a malignant solid tumor and must have disease that is resistant to or relapsed following available standard systemic therapy, or for which there is no standard systemic therapy or reasonable therapy likely to result in clinical benefit.
  • The patient must have advanced disease, defined as cancer that is either metastatic, OR locally advanced and unresectable (and for which additional radiation therapy or other locoregional therapies are not considered feasible).
  • The patient must have disease that is measurable by standard imaging techniques, per the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), or evaluable per RECIST 1.1. (For patients with prior radiation therapy, measurable lesions must be outside of any prior radiation field[s], unless disease progression has been documented at that disease site subsequent to radiation.)
  • The patient is ≥18 years old.
  • The patient has an ECOG PS of 0-2.
  • The patient has adequate baseline organ function, as demonstrated by the following:

    • Serum creatinine ≤1.5 × institutional upper limit of normal (ULN) or calculated creatinine clearance >30 mL/min.
    • Serum albumin ≥2.5 g/dL.
    • Bilirubin ≤1.5 × institutional ULN.
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × institutional ULN (patients with hepatic metastases must have AST/ALT ≤5 times ULN).
    • International normalized ratio (INR) ≤1.5 or prothrombin time (PT) ≤1.5 × ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) ≤1.5 × ULN.
  • The patient has adequate baseline hematologic function, as demonstrated by the following:

    • Absolute neutrophil count (ANC) ≥1.5×10⁹/L
    • Hemoglobin ≥8 g/dL, with no red blood cell (RBC) transfusions within the prior 14 days.
    • Platelet count ≥100×10⁹/L, with no platelet transfusions within the prior 14 days.
  • If the patient is a woman of child bearing potential (WOCBP), she has had a negative serum or urine pregnancy test within 1 week prior to treatment.
  • The patient (male and female) agrees to use acceptable contraceptive methods for the duration of time on the study, and continue to use acceptable contraceptive methods for 1 month after the last dose of SL-801.
  • The patient has signed informed consent prior to initiation of any study-specific procedures or treatment.
  • The patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.

Exclusion Criteria:

  • The patient has persistent clinically significant ≥Grade 2 toxicities from previous anticancer therapy (excluding Grade 2 chemotherapy-related neuropathy which is permitted, and excluding Grade 2-3 laboratory abnormalities if they are not associated with symptoms, are not considered clinically significant by the Investigator, and can be managed with available medical therapies).
  • The patient has received treatment with chemotherapy, external-beam radiation, or other systemic anticancer therapy within 14 days prior to C1D1 (28 days for prior nitrosourea or mitomycin-C). (Patients with advanced prostate cancer who are receiving luteinizing hormone releasing hormone [LHRH] agonists are permitted onto the study and should continue use of these agents during study treatment).
  • The patient has received treatment with an investigational systemic anticancer agent within 14 days prior to C1D1.
  • The patient has previously received treatment with SL-801 or another investigational agent that inhibits the XPO1/CRM1 pathway.
  • The patient has an additional active malignancy that may confound the assessment of the study endpoints. Patients with a past cancer history (active malignancy within 2 years prior to study entry) with substantial potential for recurrence must be discussed with the Sponsor before study entry. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ (including transitional cell carcinoma, cervical intraepithelial neoplasia), organ-confined prostate cancer with no evidence of progressive disease.
  • The patient has clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure [Appendix 1], uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
  • The patient has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that, in the Investigator's opinion, would put the patient at significant risk for pulmonary complications during the study.
  • The patient has known active or suspected brain or leptomeningeal metastases. (Central nervous system [CNS] imaging is not required prior to study entry unless there is a clinical suspicion of CNS involvement). Patients with stable, treated brain metastases are eligible provided there is no evidence of CNS disease growth on imaging for at least 3 months following radiation therapy or other locoregional ablative therapy to the CNS.
  • The patient is receiving immunosuppressive therapy for prophylaxis following a prior organ transplant (solid organ or allogeneic stem cell). Low-dose corticosteroid therapy is permitted.
  • The patient has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.
  • The patient is pregnant or breast feeding.
  • The patient has known positive status for human immunodeficiency virus active or chronic Hepatitis B or Hepatitis C.
  • The patient is oxygen-dependent.
  • The patient has any medical condition which in the opinion of the Investigator places the patient at an unacceptably high risk for toxicities.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02667873

Contact: Shay Shemesh, MS 646-502-2310

United States, Connecticut
Yale Cancer Center Recruiting
New Haven, Connecticut, United States, 06520
Principal Investigator: Patricia LoRusso, DO         
United States, Florida
Florida Cancer Specialist Recruiting
Sarasota, Florida, United States, 34236
Principal Investigator: Judy Wang, MD         
United States, Tennessee
Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Principal Investigator: Todd Bauer, MD         
United States, Texas
Mary Crowely Cancer Research Centers- Medical City Recruiting
Dallas, Texas, United States, 75230
Principal Investigator: John J Nemunaitis, MD         
University of Texas Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Principal Investigator: Kevin Courtney, MD         
United States, Washington
University of Washington, Seattle Cancer Care Alliance Recruiting
Seattle, Washington, United States, 98109
Principal Investigator: Gabriella Chiorean, MD         
Sponsors and Collaborators
Stemline Therapeutics, Inc.
  More Information

International Conference on Harmonisation. E8: General Considerations of for Clinical Trials, July 1997.
Lassen UN, Mau-Soerensen M, Kung AL, Wen PY, Lee EQ, Plotkin SR, et al. A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM). J Clin Oncol 33, 2015 (suppl; abstr 2044)
Tan DSP, Pang M-Y, Yong WP, Soo RA, Chee CE, Thian YL et al. Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers. J Clin Oncol 33, 2015 (suppl; abstr 2542).

Responsible Party: Stemline Therapeutics, Inc. Identifier: NCT02667873     History of Changes
Other Study ID Numbers: STML-801-0115
Study First Received: November 3, 2015
Last Updated: January 31, 2017 processed this record on April 28, 2017